HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Blanco-Vaca, F. Articles by Julve, J. Search for Related Content PubMed PubMed Citation Articles by Blanco-Vaca, F. Articles by Julve, J. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol. 42, 1727-1739, November 2001
Copyright © 2001 by Lipid Research, Inc.

Review Article

Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein

Correspondence to: Francisco Blanco-Vaca, To whom correspondence should be addressed., fblancova{at}hsp.santpau.es (E-mail)

Our understanding of apolipoprotein A-II (apoA-II) physiology is much more limited than that of apoA-I. However, important and rather surprising advances have been produced, mainly through analysis of genetically modified mice. These results reveal a positive association of apoA-II with FFA and VLDL triglyceride plasma concentrations; however, whether this is due to increased VLDL synthesis or to decreased VLDL catabolism remains a matter of controversy. As apoA-II-deficient mice present a phenotype of insulin hypersensitivity, a function of apoA-II in regulating FFA metabolism seems likely. Studies of human beings have shown the apoA-II locus to be a determinant of FFA plasma levels, and several genome-wide searches of different populations with type 2 diabetes have found linkage to an apoA-II intragenic marker, making apoA-II an attractive candidate gene for this disease. The increased concentration of apoB-containing lipoproteins present in apoA-II transgenic mice explains, in part, why these animals present increased atherosclerosis susceptibility. In addition, apoA-II transgenic mice also present impairment of two major HDL antiatherogenic functions: reverse cholesterol transport and protection of LDL oxidative modification. The apoA-II locus has also been suggested as an important genetic determinant of HDL cholesterol concentration, even though there is a major species-specific difference between the effects of mouse and human apoA-II. As antagonizing apoA-I antiatherogenic actions can hardly be considered the apoA-II function in HDL, this remains a topic for future investigations.

We suggest that the existence of apoA-II or apoA-I in HDL could be an important signal for specific interaction with HDL receptors such as cubilin or heat shock protein 60. — Blanco-Vaca, F., J. C. Escolà-Gil, J. M. Martín-Campos, and J. Julve. Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein. J. Lipid Res. 2001. 42: 1727–1739.

Supplementary key words: apoA-I, apoB, HDL, hyperlipidemia, hypertriglyceridemia, insulin resistance, triglycerides, type 2 diabetes, VLDL

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				G. D. Wool, C. A. Reardon, and G. S. Getz Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties J. Lipid Res., June 1, 2008; 49(6): 1268 - 1283. [Abstract] [Full Text] [PDF]

				D. Corella, D. K. Arnett, M. Y. Tsai, E. K. Kabagambe, J. M. Peacock, J. E. Hixson, R. J. Straka, M. Province, C.-Q. Lai, L. D. Parnell, et al. The -256T>C Polymorphism in the Apolipoprotein A-II Gene Promoter Is Associated with Body Mass Index and Food Intake in the Genetics of Lipid Lowering Drugs and Diet Network Study Clin. Chem., June 1, 2007; 53(6): 1144 - 1152. [Abstract] [Full Text] [PDF]

				N. J. Hime, K. J. Drew, K. Wee, P. J. Barter, and K.-A. Rye Formation of high density lipoproteins containing both apolipoprotein A-I and A-II in the rabbit J. Lipid Res., January 1, 2006; 47(1): 115 - 122. [Abstract] [Full Text] [PDF]

				S. Rodenas, S. Rodriguez-Gil, M. C. Merinero, and F. J. Sanchez-Muniz Dietary Exchange of an Olive Oil and Sunflower Oil Blend for Extra Virgin Olive Oil Decreases the Estimate Cardiovascular Risk and LDL and Apolipoprotein AII Concentrations in Postmenopausal Women J. Am. Coll. Nutr., October 1, 2005; 24(5): 361 - 369. [Abstract] [Full Text] [PDF]

				N. Rotllan, V. Ribas, L. Calpe-Berdiel, J. M. Martin-Campos, F. Blanco-Vaca, and J. C. Escola-Gil Overexpression of Human Apolipoprotein A-II in Transgenic Mice Does Not Impair Macrophage-Specific Reverse Cholesterol Transport In Vivo Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): e128 - e132. [Abstract] [Full Text] [PDF]

				S. Jayaraman, D. L. Gantz, and O. Gursky Kinetic Stabilization and Fusion of Apolipoprotein A-2:DMPC Disks: Comparison with apoA-1 and apoC-1 Biophys. J., April 1, 2005; 88(4): 2907 - 2918. [Abstract] [Full Text] [PDF]

				X. Wang and B. Paigen Genetics of Variation in HDL Cholesterol in Humans and Mice Circ. Res., January 7, 2005; 96(1): 27 - 42. [Abstract] [Full Text] [PDF]

				L. W. Castellani, P. Gargalovic, M. Febbraio, S. Charugundla, M.-L. Jien, and A. J. Lusis Mechanisms mediating insulin resistance in transgenic mice overexpressing mouse apolipoprotein A-II J. Lipid Res., December 1, 2004; 45(12): 2377 - 2387. [Abstract] [Full Text] [PDF]

				V. Ribas, J. L. Sanchez-Quesada, R. Anton, M. Camacho, J. Julve, J. C. Escola-Gil, L. Vila, J. Ordonez-Llanos, and F. Blanco-Vaca Human Apolipoprotein A-II Enrichment Displaces Paraoxonase From HDL and Impairs Its Antioxidant Properties: A New Mechanism Linking HDL Protein Composition and Antiatherogenic Potential Circ. Res., October 15, 2004; 95(8): 789 - 797. [Abstract] [Full Text] [PDF]

				X. Wang, R. Korstanje, D. Higgins, and B. Paigen Haplotype Analysis in Multiple Crosses to Identify a QTL Gene Genome Res., September 1, 2004; 14(9): 1767 - 1772. [Abstract] [Full Text] [PDF]

				M. Motizuki, T. Takei, K. Tasaka, S. Yokota, S. Kojima, T. Haga, and K. Tsurugi Low pH Facilitates Uptake of Proteins by Cells through a Non-Endocytic Pathway J. Biochem., June 1, 2004; 135(6): 713 - 719. [Abstract] [Full Text] [PDF]

				M. C. de Beer, L. W. Castellani, L. Cai, A. J. Stromberg, F. C. de Beer, and D. R. van der Westhuyzen ApoA-II modulates the association of HDL with class B scavenger receptors SR-BI and CD36 J. Lipid Res., April 1, 2004; 45(4): 706 - 715. [Abstract] [Full Text] [PDF]

				D. Sauvaget, V. Chauffeton, S. Dugue-Pujol, A.-D. Kalopissis, I. Guillet-Deniau, F. Foufelle, J. Chambaz, A. Leturque, P. Cardot, and A. Ribeiro In Vitro Transcriptional Induction of the Human Apolipoprotein A-II Gene by Glucose Diabetes, March 1, 2004; 53(3): 672 - 678. [Abstract] [Full Text] [PDF]

				J. Lotharius and P. Brundin Impaired dopamine storage resulting from {alpha}-synuclein mutations may contribute to the pathogenesis of Parkinson's disease Hum. Mol. Genet., October 1, 2002; 11(20): 2395 - 2407. [Abstract] [Full Text] [PDF]

				J. Julve, J. C. Escola-Gil, V. Ribas, F. Gonzalez-Sastre, J. Ordonez-Llanos, J. L. Sanchez-Quesada, and F. Blanco-Vaca Mechanisms of HDL deficiency in mice overexpressing human apoA-II J. Lipid Res., October 1, 2002; 43(10): 1734 - 1742. [Abstract] [Full Text] [PDF]

				J. Julve, F. Blanco-Vaca, J. Carles Escola-Gil, F. M. van't Hooft, G. Ruotolo, S. Boquist, U. de Faire, G. Eggertsen, and A. Hamsten On the Mechanisms by Which Human Apolipoprotein A-II Gene Variability Relates to Hypertriglyceridemia * Response Circulation, April 30, 2002; 105 (17): e129 - e129. [Full Text] [PDF]